

or inhibit tumor cell growth, wherein the EVs substantially lack expression of an immune suppressive factor or miR-424.

23. The method of claim **22**, wherein the tumor is an adenoma.

24. The method of claim **22**, wherein the tumor is a secondary tumor, and the vaccine is administered to the subject after a primary tumor was resected from the subject.

25. A method of preventing the growth of a secondary tumor in a subject following resection of a primary tumor, the method comprising: administering an effective amount of a vaccine comprising tumor-derived EVs of claim **1** to the subject, wherein the EVs substantially lack expression of an immune suppressive factor or miR-424.

26. The method of claim **25**, wherein the method further comprises administering a checkpoint inhibitor to the subject in need thereof.

* * * * *